MiNK Therapeutics (INKT) AI Stock Analysis

• Market Cap: $57.94M
• Dividend Yield: N/A
• Average Volume (3M): 39.56K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.19
• Revenue Growth: N/A
• EPS Growth: 41.90%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 4,522,927
• 10 Day Avg. Volume: 31,712
• 30 Day Avg. Volume: 39,559
• PEG Ratio: 0.04
• Price to Book (P/B): -1.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: -3.67
• 1Y Price Target: $39.00
• Price Target Upside: 205.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: ―

MiNK Therapeutics' overall stock score reflects significant financial challenges and negative market sentiment. The company's ongoing losses, reliance on external financing, and technical indicators pointing to potential downward momentum weigh heavily on the score. Despite promising clinical advancements and strategic partnerships, financial instability and valuation challenges remain primary concerns.

Positive Factors

Strategic Partnerships

The partnership with Autonomous Therapeutics enhances MiNK's technology platform, potentially leading to innovative treatments and strengthening its competitive position in the biotech industry.

Leadership Strength

Adding Dr. Kadlec, a leader in biodefense, could open new strategic avenues for MiNK, enhancing its capabilities in biodefense and infectious diseases, potentially broadening its market reach.

Clinical Progress

Promising clinical data in solid tumors suggests MiNK's therapies could address unmet needs in cancer treatment, potentially leading to successful product commercialization.

Negative Factors

Financial Instability

MiNK's financial instability, marked by negative equity and dependence on external funding, poses risks to its long-term operational sustainability and ability to invest in R&D.

Cash Position

A limited cash runway raises concerns about MiNK's ability to fund ongoing operations and development projects, potentially impacting its growth and innovation capabilities.

Funding Uncertainty

Uncertain funding for the GvHD study introduces risks in advancing this program, potentially delaying product development and impacting strategic goals.

MiNK Therapeutics Business Overview & Revenue Model

Company Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

How the Company Makes Money

MiNK Therapeutics makes money through the research and development of its iNKT cell therapies, which are primarily funded through a combination of private investments, public offerings, and strategic partnerships. The company generates revenue by entering into collaboration agreements with larger pharmaceutical companies who are interested in its proprietary technology platform. These partnerships may include upfront payments, milestone payments based on developmental progress, and royalties on future sales if the therapies are successfully commercialized. Additionally, MiNK might receive grants or other funding from governmental and non-governmental organizations to support its research initiatives.

MiNK Therapeutics Financial Statement Overview

Summary

MiNK Therapeutics faces significant financial challenges typical of early-stage biotech companies. The absence of revenue and substantial net losses, along with negative equity in some periods, highlight financial instability. While the company has no debt, its operations are heavily reliant on external financing, and cash flow remains negative.

Income Statement

MiNK Therapeutics has consistently reported zero revenue in recent years, indicating a lack of commercialized products or services. The company has experienced substantial net losses, with a significant negative net profit margin. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to nonexistent revenues. These financial challenges suggest the company is still in a developmental phase, typical for biotechnology firms, but underscore the need for successful product development and commercialization.

Balance Sheet

The company's balance sheet indicates a challenging financial position, with negative stockholders' equity in several years, implying liabilities exceed assets. The absence of debt is positive, but the equity ratio is highly unstable, reflecting past negative equity scenarios. MiNK Therapeutics holds a substantial amount of cash and short-term investments, which might support operations in the short term. The lack of debt provides some financial flexibility, but overall, the balance sheet shows financial instability.

Cash Flow

MiNK Therapeutics has consistently experienced negative operating and free cash flows, indicating ongoing cash consumption without generating cash through operations. Financing activities have been a primary source of cash, which may not be sustainable in the long term. The company's ability to maintain operations relies heavily on external financing rather than operational success. The absence of positive cash flow from operations highlights the need for significant improvements in commercial and operational execution.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.77B	0.00	0.00	2.70B	0.00	0.00
Gross Profit	1.88B	-215.44K	-204.62K	-28.24B	-77.96K	-55.06K
EBITDA	-9.07M	-10.57M	-22.25M	-30.83M	-27.70M	-13.74M
Net Income	-5.66B	-10.78M	-22.46M	-27.99M	-30.21M	-16.24M
Balance Sheet
Total Assets	14.96B	5.72M	4.55M	21.47M	40.24M	4.56M
Cash, Cash Equivalents and Short-Term Investments	14.28B	4.58M	3.37M	19.64M	38.89M	2.69M
Total Debt	0.00	4.92M	0.00	0.00	0.00	43.82M
Total Liabilities	0.00	25.31M	22.61M	21.87M	16.47M	58.43M
Stockholders Equity	0.00	-19.59M	-18.06M	-401.30K	23.78M	-53.87M
Cash Flow
Free Cash Flow	-3.85B	-9.56M	-15.84M	-19.12M	-13.08M	-8.43M
Operating Cash Flow	-3.85B	-9.56M	-15.76M	-18.87M	-12.83M	-8.34M
Investing Cash Flow	0.00	0.00	-73.56K	-250.05K	-248.98K	-95.21K
Financing Cash Flow	13.55B	10.82M	-407.17K	-155.60K	49.26M	11.11M

MiNK Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Negative. The current price of 12.75 is below the 20-day moving average (MA) of 13.84, below the 50-day MA of 14.33, and above the 200-day MA of 11.66, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 39.69 is Neutral, neither overbought nor oversold. The STOCH value of 39.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INKT.

MiNK Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARMP	51 Neutral	$242.38M	―	―	―	-7.55%	-13.09%
ORMP	47 Neutral	$101.28M	―	24.38%	―	―	-217.26%
EPIX	46 Neutral	―	―	―	―	―	9.03%
VERU	45 Neutral	$43.84M	―	-96.35%	―	-52.76%	43.40%
INKT	38 Underperform	$57.94M	-4.51	―	―	―	41.90%
QNCX	31 Underperform	$93.54M	―	-247.78%	―	―	2.26%

MiNK Therapeutics Corporate Events

MiNK Therapeutics Appoints Dr. Robert Kadlec to Board

MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.